Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.
Source: https://www.cbc.ca/news/health/als-drug ... 59?cmp=rss